Related Experiment Video
Updated: Jun 23, 2026
07:57
A New Method for Inducing a Depression-Like Behavior in Rats
Published on: February 22, 2018
Association between the CYP2D6*4 polymorphism and depression or anxiety in the elderly
Monique J Bijl1, Hendrika J Luijendijk, Julia F van den Berg
1Erasmus Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.
Pharmacogenomics
|April 21, 2009
Summary
The CYP2D6*4/*4 genotype, affecting serotonin metabolism, was not linked to a higher risk of depression or anxiety disorders in elderly individuals. This genetic variation does not predispose older adults to these mental health conditions.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Geriatric Psychiatry
Background:
- 5-methoxytryptamine (5-MT), a serotonin precursor, is metabolized by cytochrome P450 2D6 (CYP2D6).
- Individuals with the CYP2D6*4/*4 genotype lack CYP2D6 enzyme activity, potentially leading to altered serotonin levels.
- This genetic profile might influence susceptibility to depression and anxiety, particularly in older populations.
Purpose of the Study:
- To investigate the association between the CYP2D6*4/*4 genotype and the predisposition to depression or anxiety disorders.
- To determine if genetic variations in CYP2D6 influence mental health risks in the elderly population.
Main Methods:
- A cross-sectional study was conducted within the Rotterdam Study, a population-based cohort.
- Participants aged 55 years and older were screened for depression and anxiety disorders.
- Logistic regression analysis examined the association between the CYP2D6*4 polymorphism and the risk of these disorders.
Main Results:
- No significant association was found between the CYP2D6*4/*4 genotype and an increased risk of major depression (OR = 0.85; p = 0.72).
- The CYP2D6 genotype was not associated with minor depression (OR = 1.56; p = 0.28).
- No elevated risk of anxiety disorders was observed in carriers of the CYP2D6*4/*4 genotype (OR = 1.19; p = 0.55).
Conclusions:
- Genetic variation in the CYP2D6 gene, specifically the *4/*4 genotype, is not associated with a predisposition to depression or anxiety disorders.
- These findings suggest that CYP2D6 genotype does not play a significant role in the development of depression or anxiety in the elderly.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...